Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

COPD Therapeutics Market Outlook (2023 to 2033)

The global COPD therapeutics market garnered a market value of US$ 12,144.1 million in 2023 and is expected to accumulate a market value of US$ 20,035.5 million by 2033, registering a CAGR of 5.1% over the forecast period.

The growth of the COPD therapeutics market can be attributed to an increase in smoking and genetic disorders. The market for COPD therapeutics registered a CAGR of 4.8% during the historical period.

Report Attribute Details
Estimated Base Year Value (2022) US$ 11,668.2 million
Expected Market Value (2023) US$ 12,144.1 million
Anticipated Forecast Value (2033) US$ 20,035.5 million
Projected Growth Rate (2023 to 2033) 5.1% CAGR

Surgery is recommended in case of the extreme severity of COPD, including lung volume reduction surgery, lung transplant, and bullectomy, and the adoption of COPD therapeutics rises as COPD is one of the leading causes of death worldwide.

Triple therapy, LABA-ICS, LAMA-ICS, and other combination medications are examples of combination therapy. As using a bronchodilator and a corticosteroid separately is less effective, combination therapy is becoming more popular, positively impacting the market outlook.

Combination therapy is superior to monotherapy for treating the signs and symptoms of chronic obstructive pulmonary disease and enhancing the quality of life. Moreover, the COPD therapeutics market growth is anticipated to rise as a result of a rise in the number of patients who are successfully treated with combination therapy but did not improve after receiving bronchodilators or corticosteroids.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Which Are Some Prominent Drivers of the COPD Therapeutics Market?

Lifestyle change is responsible for increasing the habits like smoking and increase in the number of genetic disorders, which in turn are responsible for raising the number of COPD patients and expanding the COPD therapeutics market size.

Other factors that can boost the revenue from the COPD therapeutics market are rising healthcare expenditures, leading to the adoption of COPD treatments in emerging economies. The demand for COPD therapeutics can also be owed to an increase in the level of awareness which has also led to the early diagnosis of COPD so that people can go for the treatment of the disease.

Additionally, it is projected that new product launches and advances in the global market for Chronic Obstructive Pulmonary therapeutics in respiratory illness therapy will aid in the industry's expansion. Betterment of the healthcare infrastructure in the Asia Pacific and the Middle East, and Africa is also responsible for the revenue growth of the COPD therapeutics market during the forecast period.

What Are the Challenges Faced by the COPD Therapeutics Market?

Factors that can limit the growth of the therapeutic enzymes over the forecast period include the fact that not all patients suffering from COPD are aware of the fact that they are suffering from the disease and therefore do not go for the treatment of the disease.

Also, sometimes people get to know about their disease when only medication and therapies, and surgery can’t cure the disease becomes mandatory. This factor can also lead to sluggish growth in the revenue from the COPD therapeutics market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

How Is the Prevalence of COPD Escalating Demand for COPD Therapeutics in North America?

Region North America
Market Share % (2022) 36.2%

According to National Heart, Lung, and Blood Institute, more than 15 million people are affected by COPD. This has increased the dependency on COPD therapeutics to access early treatment for the same. In addition, the strong presence of key players in the region is accelerating the growth of the COPD therapeutics market.

Moreover, developing health infrastructure is fuelling the growth of the COPD therapeutics market. Thus, due to the aforementioned reasons, North America is expected to possess more than 36.2% market share for COPD therapeutics in 2023.

How are Government Initiatives Augmenting Demand for COPD Therapeutics in Europe?

Region Europe
Market Share % (2022) 29.8%

According to Asthma Lung UK+, more than 1.3 million people suffer from COPD. This has led the country's government to design initiatives to create awareness regarding COPD. In addition, the increasing geriatric population in the country is contributing to the growth of the COPD market.

Furthermore, the growing inclination towards early treatment positively influences the market's growth. Thus, due to the reasons mentioned above, Europe is expected to hold a more than 29.8% COPD therapeutics market share in 2023.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

What Are A Few Key Start-Ups in The COPD Therapeutics Market?

Key start-up players in the COPD therapeutics market are Omnispirant, Atriva Therapeutics, Altavant Sciences, Exvastat, and ReAlta Life Sciences.

  • ReAlta Life Sciences, a key start-up in the COPD therapeutics market develops engineered peptides to harness the power of the immune system. In addition, the drug also works for COVID-19 patients.
  • Spirosure, a US-based start-up, raised US$ 32 million in funding, aimed at making the lives of people with respiratory disorders like COPD, asthma, cystic fibrosis, and pulmonary hypertension better by developing breath-based diagnostic and monitoring tools.

How Strong Is the Competition in The COPD Therapeutics Market?

The COPD market is consolidated, with only a few significant firms present, and the primary strategies used by the top companies are product portfolio expansion and mergers and acquisitions.

One of the major recent developments in the COPD therapeutics market is when AstraZeneca’s Bevespi Aerospherehas received approval in China as a maintenance treatment to relieve symptoms in patients suffering from COPD.

Key players

  • Pfizer Inc.
  • Adamis Laboratories Inc.
  • GlaxoSmithKline plc.
  • AstraZeneca
  • Merk & Co.
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries

Report Scope

Report Attribute Details
Market Value in 2023 US$ 12,144.1 million
Market Value in 2033 US$ 20,035.5 million
Growth Rate CAGR of 5.1% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Component
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • The United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • GCC
  • South Africa
Key Companies Profiled
  • Pfizer Inc.
  • Adamis Laboratories Inc.
  • GlaxoSmithKline plc
  • AstraZeneca
  • Merk & Co
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries
Customization Available Upon Request

Key Segments Profiled in the COPD Therapeutics Industry Survey

By Component:

  • COPD Therapeutics Drug Class
  • Bronchodilators
  • Steroids
  • Phosphodiesterase-4 inhibitors
  • Theophylline
  • Antibiotics
  • COPD Therapeutics Delivery Systems
  • Oral
  • Inhalation

By End User:

  • Hospitals
  • Private Clinics
  • Outpatient Departments

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the market value in 2023?

The market in 2023 is valued at US$ 12,144.1 million.

How was the market’s historical performance?

The market rose at a 4.8% CAGR from 2018 to 2022.

What is the likely CAGR until 2033?

The market will register a 5.1% CAGR until 2033.

What will be the market value in 2033?

By 2033, the market will reach US$ 20,035.5 million.

What was Europe’s market share in 2022?

Europe’s market share in 2022 was 29.8%.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Component

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Component, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Component, 2023 to 2033

        5.3.1. Drug Class

        5.3.2. Bronchodilators

        5.3.3. Steroids

        5.3.4. Phosphodiesterase-4 inhibitors

        5.3.5. Theophylline

        5.3.6. Antibiotics

        5.3.7. Delivery Systems

        5.3.8. Oral

        5.3.9. Inhalation

    5.4. Y-o-Y Growth Trend Analysis By Component, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Component, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Private Clinics

        6.3.3. Outpatient Departments

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Component

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Component

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Component

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Component

        9.3.3. By End User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Component

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Component

        10.3.3. By End User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Component

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Component

        11.3.3. By End User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Component

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Component

        12.3.3. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Component

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Component

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Component

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Component

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Component

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Component

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Component

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Component

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Component

            15.5.2.2. By End User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Component

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Component

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Component

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Component

            15.9.2.2. By End User

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Component

            15.10.2.2. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Component

            15.11.2.2. By End User

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Component

            15.12.2.2. By End User

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Component

            15.13.2.2. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Component

            15.14.2.2. By End User

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Component

            15.15.2.2. By End User

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Component

            15.16.2.2. By End User

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Component

            15.17.2.2. By End User

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Component

            15.18.2.2. By End User

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Component

            15.19.2.2. By End User

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Component

            15.20.2.2. By End User

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Component

            15.21.2.2. By End User

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Component

            15.22.2.2. By End User

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Component

            15.23.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Component

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Pfizer Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Adamis Laboratories Inc.

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. GlaxoSmithKline plc.

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. AstraZeneca Plc

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Merk & Co.

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Novartis AG

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Mylan N.V.

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. Teva Pharmaceutical Industries

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. Abbott Laboratories

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. Almirall

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

        17.1.11. Astellas Pharma

            17.1.11.1. Overview

            17.1.11.2. Product Portfolio

            17.1.11.3. Profitability by Market Segments

            17.1.11.4. Sales Footprint

            17.1.11.5. Strategy Overview

                17.1.11.5.1. Marketing Strategy

        17.1.12. Boehringer Ingelheim Pharmaceuticals, Inc.

            17.1.12.1. Overview

            17.1.12.2. Product Portfolio

            17.1.12.3. Profitability by Market Segments

            17.1.12.4. Sales Footprint

            17.1.12.5. Strategy Overview

                17.1.12.5.1. Marketing Strategy

        17.1.13. Orion Corporation

            17.1.13.1. Overview

            17.1.13.2. Product Portfolio

            17.1.13.3. Profitability by Market Segments

            17.1.13.4. Sales Footprint

            17.1.13.5. Strategy Overview

                17.1.13.5.1. Marketing Strategy

        17.1.14. Sunovion Pharmaceuticals, Inc.

            17.1.14.1. Overview

            17.1.14.2. Product Portfolio

            17.1.14.3. Profitability by Market Segments

            17.1.14.4. Sales Footprint

            17.1.14.5. Strategy Overview

                17.1.14.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Chronic Obstructive Pulmonary Disease (COPD) Market

Published : December 2022

Explore Healthcare Insights

View Reports